What Not to Take With Retatrutide: Interactions, Foods & Safety

What not to take with retatrutide is an important consideration for anyone involved in or considering clinical trials of this investigational triple incretin receptor agonist. Retatrutide acts on GLP-1, GIP, and glucagon receptors and is being studied for obesity and type 2 diabetes. Although it has not yet received MHRA or EMA marketing authorisation, its pharmacological profile raises clinically relevant questions about interactions with antidiabetic medicines, anticoagulants, oral contraceptives, and drugs with a narrow therapeutic index. This article summarises current guidance extrapolated from authorised GLP-1 and GLP-1/GIP receptor agonists.

Medicines That May Interact With Retatrutide

Insulin and sulfonylureas carry the highest interaction risk with retatrutide, substantially increasing hypoglycaemia risk; caution is also required with warfarin, oral contraceptives, DPP-4 inhibitors, and other GLP-1 receptor agonists.

Retatrutide is an investigational triple incretin receptor agonist acting on GLP-1, GIP, and glucagon receptors, currently undergoing clinical trials for the treatment of obesity and type 2 diabetes. It has not yet received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA). Definitive interaction guidance will only be available once a UK Summary of Product Characteristics (SmPC) is published; the information below is extrapolated from authorised GLP-1 and GLP-1/GIP receptor agonists (such as semaglutide and tirzepatide) and should be interpreted accordingly.

The most clinically significant interaction concern involves antidiabetic medicines. Because retatrutide lowers blood glucose through multiple hormonal pathways, combining it with insulin or sulfonylureas (such as gliclazide or glibenclamide) may substantially increase the risk of hypoglycaemia. Dose reduction of these agents may be required under medical supervision, in line with class labelling for authorised GLP-1 receptor agonists.

Patients taking beta-blockers alongside insulin or sulfonylureas should be aware that beta-blockers can mask the adrenergic symptoms of hypoglycaemia (such as tremor and palpitations), making low blood glucose harder to recognise. Closer glucose monitoring is advisable in this situation.

Other medicines warranting caution include:

• Oral contraceptives — the tirzepatide SmPC (Mounjaro, MHRA/emc) advises considering non-oral or additional barrier contraception for at least 4 weeks after initiation and after each dose increase, due to a potential reduction in oral contraceptive exposure during these periods. Whether retatrutide carries the same risk is not yet established; patients using oral hormonal contraceptives should discuss this with their prescriber pending a retatrutide SmPC.

• Warfarin and other anticoagulants — UK SmPCs for authorised GLP-1 receptor agonists (for example, semaglutide) advise more frequent INR monitoring when starting treatment or changing the dose. Patients taking warfarin should ensure their anticoagulation is checked more regularly during any initiation or dose-escalation period.

• DPP-4 inhibitors — combining a GLP-1 receptor agonist with a DPP-4 inhibitor (such as sitagliptin or alogliptin) is generally not recommended in UK practice, as NICE guidance (NG28) and the BNF note limited additional clinical benefit from this combination. The same principle is likely to apply to retatrutide.

• Other GLP-1 receptor agonists — combining retatrutide with another GLP-1 receptor agonist is not recommended, as this is not supported by clinical evidence and may increase the risk of adverse effects.

Patients and prescribers should consult the most current SmPC once available, alongside relevant NICE guidance, before initiating retatrutide alongside any existing medication regimen.

Foods, Supplements and Substances to Avoid

Alcohol should be consumed within NHS low-risk limits as it can worsen gastrointestinal side effects and compound hypoglycaemia risk when used alongside insulin or sulfonylureas; herbal supplements with hypoglycaemic properties such as berberine or fenugreek warrant caution.

Whilst retatrutide is not yet licensed in the UK, its pharmacological profile, particularly its effect on slowing gastric emptying and reducing appetite, has implications for how certain foods, supplements, and substances may interact with the medicine.

Alcohol warrants consideration. The primary hypoglycaemia risk from alcohol is most relevant when retatrutide is used alongside insulin or sulfonylureas, as alcohol can independently lower blood glucose and may compound the glucose-lowering effects of these agents. Even without such combinations, alcohol can irritate the gastrointestinal tract, and since nausea, vomiting, and gastrointestinal discomfort are among the most commonly reported side effects of GLP-1-based therapies, alcohol consumption may worsen these symptoms. Moderation is advisable; patients should aim to stay within the UK low-risk drinking limits as set out in NHS alcohol-units guidance (no more than 14 units per week, spread across three or more days, with several alcohol-free days).

With regard to dietary supplements, patients should be aware of the following:

• Herbal supplements with possible hypoglycaemic properties — such as berberine, bitter melon, or fenugreek — are sometimes cited as potentially enhancing blood glucose-lowering effects, though the clinical evidence for these interactions is limited and variable. As a precaution, patients using such supplements alongside insulin or sulfonylureas should discuss this with their GP or pharmacist and monitor their blood glucose more closely.

• High-fat or high-sugar meals — whilst not contraindicated, these may worsen gastrointestinal side effects, particularly during the dose escalation phase. A balanced, nutrient-rich diet is recommended in line with NHS dietary guidance for weight management and diabetes.

Patients are advised to discuss any supplements they are taking with their GP or pharmacist before starting retatrutide. There is no formally established link between specific foods and serious adverse outcomes with retatrutide at this stage, but caution is prudent given the drug's mechanism of action.

How Retatrutide Affects Other Medications in Your Body

Retatrutide may delay gastric emptying, potentially altering absorption of co-administered oral medicines; drugs with a narrow therapeutic index, including digoxin, ciclosporin, and antiepileptics, require closer monitoring during initiation and dose escalation.

One of the most pharmacologically relevant features of retatrutide, shared with other GLP-1 receptor agonists such as semaglutide and liraglutide, is its potential to delay gastric emptying. This means that food and orally administered medicines may move more slowly through the stomach and into the small intestine, where most drug absorption occurs. This could theoretically alter the peak plasma concentration (Cmax) and time to peak concentration (Tmax) of co-administered oral drugs. UK SmPCs for authorised GLP-1 receptor agonists (for example, semaglutide) note that gastric emptying effects may attenuate with continued dosing, and that no clinically relevant effect on overall drug exposure has been observed for most oral medicines; however, individual monitoring remains prudent for medicines with a narrow therapeutic index.

Medicines with a narrow therapeutic index, where small changes in blood concentration can have significant clinical consequences, merit particular attention. Based on class data from authorised GLP-1 receptor agonist SmPCs, prescribers should consider therapeutic drug monitoring or clinical assessment when initiating retatrutide in patients taking medicines such as:

• Digoxin — used for heart failure and atrial fibrillation.

• Ciclosporin and tacrolimus — immunosuppressants where consistent drug levels are critical.

• Antiepileptic drugs such as phenytoin or carbamazepine — where subtherapeutic levels could precipitate seizures.

• Levothyroxine — data from oral semaglutide (Rybelsus) suggest a possible effect on levothyroxine absorption; the clinical relevance for injectable incretin therapies is uncertain, but thyroid function should be monitored if symptoms of under- or over-treatment emerge.

These are precautionary considerations extrapolated from class data; the clinical significance will vary between individual medicines and patients.

Peri-operative considerations are also relevant. The MHRA has issued a Drug Safety Update advising that patients taking GLP-1 receptor agonists should inform their anaesthetist or surgical team before any procedure involving anaesthesia or deep sedation. Delayed gastric emptying may increase the risk of regurgitation and aspiration. Patients should follow the fasting instructions provided by their surgical team and discuss whether temporary interruption of treatment before the procedure is appropriate, in line with local anaesthetic policy.

Claims that retatrutide's glucagon receptor activity may interact with statins or fibrates are not currently supported by published clinical data and are not included here.

Patients should never adjust or discontinue any prescribed medication without first consulting their GP or specialist. Pharmacists can provide valuable guidance on monitoring and the management of any potential interactions.

Who Should Exercise Extra Caution or Avoid Retatrutide

Patients with a history of pancreatitis, medullary thyroid carcinoma, MEN2, severe gastroparesis, gallbladder disease, or diabetic retinopathy should seek specialist advice, as should pregnant women, children, and those with severe renal or hepatic impairment.

Certain patient groups may face a higher risk of adverse effects or complications with retatrutide and should approach its use with particular caution, or may be advised to avoid it altogether pending further evidence.

Patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2) should seek specialist advice before using any incretin-based therapy. Preclinical studies in rodents have shown an association between GLP-1 receptor activation and thyroid C-cell changes, although a direct causal link in humans has not been established, and UK/EU SmPCs for authorised GLP-1 receptor agonists do not list MTC or MEN2 as a formal contraindication. Patients and clinicians should remain alert to symptoms such as a new neck lump, hoarseness, or difficulty swallowing, and seek prompt medical assessment if these occur.

Other groups requiring careful evaluation include:

• Patients with a history of pancreatitis — a causal relationship between incretin-based therapies and pancreatitis has not been definitively established, but UK SmPCs advise caution in those with a prior history. Treatment should be stopped and urgent medical attention sought if symptoms of pancreatitis occur (severe, persistent abdominal pain radiating to the back, with or without vomiting).

• Patients with gallbladder disease or a history of gallstones — GLP-1 receptor agonist SmPCs (including semaglutide) include a class warning for gallbladder disease, including cholelithiasis and cholecystitis. Patients should seek prompt medical review if they develop persistent right upper quadrant pain, fever, or jaundice.

• Patients with pre-existing diabetic retinopathy — a class caution exists (based on semaglutide data) that rapid improvement in glycaemic control may be associated with early worsening of diabetic retinopathy. Appropriate ophthalmic monitoring should be arranged in line with clinical guidance.

• Individuals with severe gastroparesis — delayed gastric emptying could worsen symptoms in this group, and retatrutide is likely to be unsuitable.

• Patients planning surgery or procedures under anaesthesia — delayed gastric emptying may increase aspiration risk. The surgical and anaesthetic team should be informed, and temporary interruption of treatment before the procedure should be discussed in line with local policy and the MHRA Drug Safety Update.

• Pregnant or breastfeeding women — there is currently insufficient safety data to support use during pregnancy or lactation.

• Patients with severe renal or hepatic impairment — whether dose adjustments or avoidance are necessary will depend on the pharmacokinetic data presented in the eventual retatrutide SmPC.

• Children and adolescents — retatrutide has not been studied in paediatric populations and should not be used outside of approved clinical trial settings.

A thorough medical history and clinical assessment by a qualified prescriber are essential before initiating treatment.

Guidance From Your GP or Prescriber Before Starting Treatment

A comprehensive medicines reconciliation review with your GP or prescriber is essential before starting retatrutide, covering all current medicines, supplements, medical history, and lifestyle factors, with baseline investigations arranged as clinically indicated.

Before starting retatrutide, or any new medicine, it is essential to have a comprehensive consultation with your GP, specialist, or prescriber. This is particularly important given that retatrutide is still in clinical development and is not yet available as a licensed treatment through the NHS or private prescribing channels in the UK. Patients should be cautious of unregulated sources offering retatrutide outside of approved clinical trials.

During your consultation, your prescriber should conduct a thorough medicines reconciliation review, which involves:

• Listing all current prescription medicines, including inhalers, patches, and injections.

• Reviewing over-the-counter medicines and any herbal or nutritional supplements.

• Assessing your medical history for conditions that may increase the risk of interactions or adverse effects.

• Discussing lifestyle factors, including alcohol intake, diet, and physical activity levels.

Your prescriber may arrange baseline investigations tailored to your individual circumstances and the indication for treatment. In line with NICE guidance (for example, NG28 for type 2 diabetes; TA875 for weight management), these may include blood glucose monitoring, HbA1c (where relevant), and renal and liver function tests where clinically indicated. Routine thyroid function testing is not a standard requirement before starting GLP-1 or GIP-based therapies in UK practice, but may be arranged if there is a specific clinical reason.

If you use oral hormonal contraceptives, discuss this with your prescriber. Based on the tirzepatide SmPC (Mounjaro), additional or non-oral contraception is advisable for at least 4 weeks after initiation and after each dose increase of a GLP-1/GIP-based therapy. Whether the same timeframe applies to retatrutide is not yet established; your prescriber can advise on the most appropriate approach pending a retatrutide SmPC.

If you take beta-blockers and are also using insulin or a sulfonylurea, discuss hypoglycaemia awareness with your prescriber, as beta-blockers can mask some of the warning signs of low blood glucose.

If you are currently taking medicines with a narrow therapeutic index, your prescriber may recommend closer monitoring during the initiation and dose escalation phases.

If you are planning any surgical procedure or intervention requiring anaesthesia or deep sedation, inform your surgical and anaesthetic team that you are taking retatrutide. Discuss whether temporary interruption before the procedure is appropriate, in line with local policy and MHRA guidance on aspiration risk with GLP-1-based therapies.

It is important to attend all follow-up appointments and to report any new or worsening symptoms promptly. Never start, stop, or adjust any medication without professional advice, and always inform any other healthcare professional, including dentists and pharmacists, that you are taking retatrutide.

Reporting Side Effects and Interactions in the UK

Suspected side effects and interactions with retatrutide outside a clinical trial should be reported via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk; trial participants should report directly to the trial sponsor and principal investigator.

In the UK, the reporting of suspected side effects and drug interactions is a vital component of ongoing drug safety monitoring. The MHRA operates the Yellow Card scheme, which allows patients, carers, and healthcare professionals to report suspected adverse drug reactions and interactions outside of clinical trials. Reports can be submitted online at yellowcard.mhra.gov.uk, via the Yellow Card app, or through a paper form available from pharmacies.

For retatrutide specifically, as it remains an investigational medicine, any adverse events experienced within a clinical trial setting should be reported directly to the trial sponsor and principal investigator in accordance with the trial protocol. Regulatory oversight of clinical trials in the UK is managed by the MHRA in conjunction with the Health Research Authority (HRA).

Patients and healthcare professionals should seek urgent medical attention if any of the following occur:

• Signs of severe hypoglycaemia — confusion, loss of consciousness, or seizures.

• Symptoms suggestive of pancreatitis — severe, persistent abdominal pain radiating to the back, with or without vomiting.

• Severe or prolonged vomiting with signs of dehydration — such as dizziness, reduced urine output, or extreme thirst — which may indicate a risk of acute kidney injury.

• Allergic reactions — including rash, swelling of the face or throat, or difficulty breathing.

• Unexplained neck lumps, hoarseness, or difficulty swallowing, which should be assessed promptly.

• Persistent right upper quadrant pain, fever, or jaundice, which may suggest gallbladder disease.

Healthcare professionals are encouraged to report all suspected interactions and adverse drug reactions via the Yellow Card scheme for medicines used outside of a trial, even if causality is uncertain. Every report contributes to building the evidence base for drug safety in the UK population as new medicines like retatrutide move closer to clinical use.

Frequently Asked Questions